India Patent Office Weighs Cipla, Natco Challenges To Bayer’s Nexavar
This article was originally published in PharmAsia News
Executive Summary
India’s Mumbai Patent Office is expected to decide soon whether Bayer’s Nexavar (sorafenib) for treating liver and kidney cancers can be allowed on the market in generic form.